RIGEL PHARMACEUTICALS INC
RIGLLatest QuantConomy context for RIGL: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
RIGEL PHARMACEUTICALS INC
QuantConomy has a structured record for RIGL. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- RIGL
- Name
- RIGEL PHARMACEUTICALS INC
- Coverage
- 3 market/data records
- Sources
- alphavantage alpaca fmp sec nasdaq openfigi
Recent signals for RIGL
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| executive change | neutral | 75 | Jul 1, 08:57 PM | RIGL filed 8-K: Director or Officer Changes - 1 material event - [strong neutral signal] |
| earnings release | neutral | 40 | Jan 12, 12:00 AM | RIGL filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-01-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| earnings release | neutral | 40 | Mar 3, 12:00 AM | RIGL filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-03-03. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| RIGL | NASDAQ | alphavantage | Rigel Pharmaceuticals |
| RIGL | NASDAQ | alpaca | Rigel Pharmaceuticals, Inc. Common Stock |
| RIGL | NASDAQ | fmp | Rigel Pharmaceuticals, Inc. |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | HANNAH ALISON L. | EVP, Chief Medical Officer | grant | 24,400 | $0.00 | $0 | 4 on EDGAR |
| Jun 22, 2026 | Ali-Jackson Kamil | Director | sale | 2,500 | $35.00 | $87,500 | 4 on EDGAR |
| Jun 17, 2026 | Schorno Dean L | EVP & Chief Financial Officer | grant | 7,394 | — | — | 4 on EDGAR |
| Jun 17, 2026 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | grant | 7,394 | — | — | 4 on EDGAR |
| Jun 17, 2026 | RODRIGUEZ RAUL R | CEO, President | grant | 31,700 | — | — | 4 on EDGAR |
| Jun 17, 2026 | Santos David A | EVP, Chief Commercial Officer | grant | 7,394 | — | — | 4 on EDGAR |
| Jun 17, 2026 | Rojkjaer Lisa | EVP, Chief Medical Officer | grant | 9,375 | — | — | 4 on EDGAR |
| Jun 1, 2026 | Santos David A | EVP, Chief Commercial Officer | other | 874 | $29.86 | $26,098 | 4 on EDGAR |
| Jun 1, 2026 | RODRIGUEZ RAUL R | CEO, President | other | 2,424 | $29.86 | $72,381 | 4 on EDGAR |
| Jun 1, 2026 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | other | 877 | $29.86 | $26,187 | 4 on EDGAR |
| Jun 1, 2026 | Rojkjaer Lisa | EVP, Chief Medical Officer | other | 850 | $29.86 | $25,381 | 4 on EDGAR |
| Jun 1, 2026 | Schorno Dean L | EVP & Chief Financial Officer | exercise | 1,200 | $18.70 | $22,440 | 4 on EDGAR |
| May 26, 2026 | Ali-Jackson Kamil | Director | sale | 2,500 | $29.17 | $72,925 | 4 on EDGAR |
| May 15, 2026 | Frohlich Mark W | Director | grant | 5,750 | $0.00 | $0 | 4 on EDGAR |
| May 15, 2026 | HANNAH ALISON L. | Director | grant | 5,750 | $0.00 | $0 | 4 on EDGAR |
| May 15, 2026 | MILLER MICHAEL PATRICK | Director | grant | 5,750 | $0.00 | $0 | 4 on EDGAR |
| May 15, 2026 | LAPOINTE ANTHONY GREGG | Director | grant | 5,750 | $0.00 | $0 | 4 on EDGAR |
| May 15, 2026 | MOOS WALTER H | Director | grant | 5,750 | $0.00 | $0 | 4 on EDGAR |
| May 15, 2026 | Wasman Jane | Director | grant | 5,750 | $0.00 | $0 | 4 on EDGAR |
| May 15, 2026 | Ali-Jackson Kamil | Director | grant | 5,750 | $0.00 | $0 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query RIGL context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access